NBY NovaBay Pharmaceuticals Inc New

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces that it will report 2017 second quarter financial results after market close on Thursday, August 10. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.

    DATE: Thursday, August 10 TIME: 4:30 p.m. ET / 1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S. 702-495-1913 from outside the U.S. Enter conference identification number 56306358  

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 12:59 p.m. Eastern time September 10, 2017, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 56306358. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Stay informed on NovaBay's progress:Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

NovaBay ContactsFor NovaBay Avenova purchasing information, please contact:1-800-890-0329www.Avenova.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005218/en/

NovaBay Pharmaceuticals, Inc.Jack McGovernChief Financial Officer510-899-8800jmcgovern@novabay.comorInvestor ContactLHA Investor RelationsJody Cain310-691-7100jcain@lhai.com